Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000071

Senior Vice President, Finance sold 9,999 shares at an average $84.63 ($846,180)

  • Senior Vice President, Finance acquired 9,999 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Agarwal Arjun · Senior Vice President, Finance

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2026-07-13 Exercise or conversion : show line 1 in the form 10b5-1 +8,541 $12.50 $106,763 23,853 D
2026-07-13 Exercise or conversion : show line 2 in the form 10b5-1 +1,458 $34.39 $50,141 25,311 D
2026-07-13 Sale : show line 3 in the form 10b5-1 −300 $83.07 $24,920 25,011 D
2026-07-13 Sale : show line 4 in the form 10b5-1 −3,743 $84.26 $315,369 21,268 D
2026-07-13 Sale : show line 5 in the form 10b5-1 −5,656 $84.90 $480,201 15,612 D
2026-07-13 Sale : show line 6 in the form 10b5-1 −300 $85.63 $25,690 15,312 D
Open-market sales · 9,999 sh · avg $84.63 · $846,180

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-07-13 Exercise or conversion : show line 7 in the form 10b5-1 Employee Stock Option (right to buy) −8,541 101,459 D
2026-07-13 Exercise or conversion : show line 8 in the form 10b5-1 Employee Stock Option (right to buy) −1,458 61,250 D
Loading xslF345X06/form4.xml…